Gelonghui, May 8 | Puni Test (300887.SZ) said on the investor interactive platform that Hubei Zhongjia Synthetic Pharmaceutical Co., Ltd. has a GMP production system and production capacity for APIs, and is the “last mile” to open up a one-stop biomedical technology platform for the company. At this point, the Penney Group can provide full-process technical support for biomedical research and development. Currently, there is no biosynthesis business.
谱尼测试(300887.SZ)：目前未开展生物合成业务
Penile test (300887.SZ): Currently no biosynthesis business
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.